Research & Development Market Research Reports & Industry Analysis
Bringing R&D costs and times down, therefore, means there are many opportunities to improve efficiencies, advance technological innovation, and economize and optimize. The pharmaceutical R&D category tracks both drug pipeline reports, competitive R&D strategies, and markets important and ancillary to the research efforts themselves, including activities in the biotech and sector that impinge upon the process.
Research & Development Industry Research & Market Reports
-
Rat Model
... CAGR of 7.1% over the analysis period 2024-2030. Inbred Rat Model, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$901.6 Million by the end of the ... Read More
-
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
... Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2024-2030. Medication Treatment, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$5.5 Billion ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$112.8 Billion by the end of the analysis period. ... Read More
-
Stromal Vascular Fraction
... at a CAGR of 4.5% over the analysis period 2024-2030. Isolation Products, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$99.5 Million by the end of ... Read More
-
Marine Biotechnology
... CAGR of 8.4% over the analysis period 2024-2030. Biomaterials, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$6.5 Billion by the end of the analysis period. ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA Tool, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end ... Read More
-
Immune Checkpoint Inhibitors
... at a CAGR of 16.5% over the analysis period 2024-2030. PD-1, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$109.0 Billion by the end of the ... Read More
-
Neuroscience
... 3.9% over the analysis period 2024-2030. Neuroscience Instruments, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth ... Read More
-
PEGylated Proteins
... CAGR of 9.1% over the analysis period 2024-2030. PEGylated Proteins Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the ... Read More
-
Life Science Analytics
... at a CAGR of 13.3% over the analysis period 2024-2030. Life Science Analytics Services, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$44.7 Billion by the ... Read More
-
Growth Factors (Blood and Tissue)
... Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Interferons, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$78.2 Billion by ... Read More
-
Albumin
... 3.8% over the analysis period 2024-2030. Human Serum Albumin, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$902.4 Million by the end of the analysis period. ... Read More
-
Synthetic Protein
... CAGR of 15.7% over the analysis period 2024-2030. The U.S. Market is Estimated at US$87.8 Million While China is Forecast to Grow at 20.2% CAGR The Synthetic Protein market in the U.S. is estimated at ... Read More
-
Simultaneous-Functionality Analyzers
... CAGR of 5.0% over the analysis period 2024-2030. Chemical & Material Manufacturers End-Use, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$134.6 Million by the end ... Read More
-
Interferon
... 2.8% over the analysis period 2024-2030. Interferon Beta, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth ... Read More
-
Healthcare Contract Development and Manufacturing Organization
... reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach ... Read More
-
RNA Interference (RNAi)
... at a CAGR of 10.0% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$118.1 Billion by ... Read More
-
Humanized Mouse and Rat Model
... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Humanized Rat Models, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$13.6 ... Read More
-
Beta Interferon
... CAGR of 3.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$968.9 Million While China is Forecast to Grow at 4.5% CAGR The Beta Interferon market in the U.S. is estimated at ... Read More
-
Biotechnology
... 8.5% over the analysis period 2024-2030. DNA Sequencing Technology, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$33.5 Billion by the end of the analysis period. ... Read More
-
43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025
... health care investment symposium in the industry. This year’s invitation-only conference provided key insights into the evolving strategies, pipeline advancements, and market trends shaping the biopharmaceutical industry, including acquisitions, innovative pipeline developments, and strategic shifts ... Read More
-
Innovation Insights: AI for drug target identification
... natural language processing, enable the analysis of complex biological data, identifying potential drug targets with higher accuracy and speed than traditional methods. These technologies can predict protein-ligand interactions, analyze genetic and epigenetic data, and identify ... Read More
-
Innovation Insights: Targeted Delivery of Oligos to Kidney/Heart
... or RNA molecules that have the potential to treat a wide range of diseases, but their effectiveness is often limited by the challenges of delivering them to the right location in the body. The book ... Read More
-
Cold Plasma Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
Research Assistance
